Hypofractionated chemoradiation for head and cancer: data from the PET NECK trial

Research output: Contribution to journalArticlepeer-review

Standard

Hypofractionated chemoradiation for head and cancer : data from the PET NECK trial. / Vreugdenhil, M.; Fong, Charles; Sanghera, Paul; Hartley, Andrew; Dunn, Janet; Mehanna, Hisham.

In: Oral Oncology, Vol. 113, 105112, 02.2021.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{03fe0d70cace46458921360b2ae20735,
title = "Hypofractionated chemoradiation for head and cancer: data from the PET NECK trial",
abstract = "There has been increased interest in hypofractionated accelerated chemoradiation for head and neck cancer during the recent first peak of the COVID-19 pandemic. Prospective data regarding this approach from randomised trials is lacking. In the PET NECK study, 564 patients with squamous cell carcinoma of the head and neck receiving definitive chemoradiation were randomised to either planned neck dissection or PET CT scan guided surveillance. In this surgical trial, three radiotherapy fractionation schedules delivered over 7, 6 or 4 weeks were permitted with synchronous chemotherapy. The purpose of this study was to determine efficacy and quality of life outcomes associated with the use of these schedules. Primary local control and overall survival in addition to quality of life measures at immediately post treatment and 6, 12 and 24 months post-treatment were compared between the three fractionation cohorts. In the 525 patients where fractionation data was available, 181 (34%), 288 (55%) and 56 (11%) patients received 68–70 Gy in 34–35 fractions (#), 60–66 Gy in 30# and 55 Gy in 20# respectively. At a minimum follow up of two years following treatment there was no significant difference between the three fractionation schemes in local control, overall survival or any quality of life measure. Despite the obvious limitations of this study, some data is provided to support the use of hypofractionated accelerated chemoradiation to avoid delays in cancer treatment and reduce hospital visits during the peak of a pandemic. Data from on-going randomised trials examining hypofractionated chemoradiation may be useful for selecting fractionation schedules during future pandemics.",
keywords = "COVID 19, Fractionation, Head and neck cancer, Hypofractionated chemoradiation, Pandemic",
author = "M. Vreugdenhil and Charles Fong and Paul Sanghera and Andrew Hartley and Janet Dunn and Hisham Mehanna",
note = "Funding Information: HM reports personal fees from Warwickshire Head Neck Clinic Ltd, personal fees from AstraZeneca, personal fees from MSD, Sanofi Pasteur, Merck, grants from GSK Biologicals, MSD, Sanofi Pasteur, Silence Therapeutics, GSK PLC, AstraZeneca, other from Sanofi Pasteur, MSD, Merck, outside the submitted work. The original PET neck study was supported by academic grants from the National Institute for Health Research Health Technology Assessment Programme (06/302/129) and Cancer Research UK (C19677/A9674), ",
year = "2021",
month = feb,
doi = "10.1016/j.oraloncology.2020.105112",
language = "English",
volume = "113",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Hypofractionated chemoradiation for head and cancer

T2 - data from the PET NECK trial

AU - Vreugdenhil, M.

AU - Fong, Charles

AU - Sanghera, Paul

AU - Hartley, Andrew

AU - Dunn, Janet

AU - Mehanna, Hisham

N1 - Funding Information: HM reports personal fees from Warwickshire Head Neck Clinic Ltd, personal fees from AstraZeneca, personal fees from MSD, Sanofi Pasteur, Merck, grants from GSK Biologicals, MSD, Sanofi Pasteur, Silence Therapeutics, GSK PLC, AstraZeneca, other from Sanofi Pasteur, MSD, Merck, outside the submitted work. The original PET neck study was supported by academic grants from the National Institute for Health Research Health Technology Assessment Programme (06/302/129) and Cancer Research UK (C19677/A9674),

PY - 2021/2

Y1 - 2021/2

N2 - There has been increased interest in hypofractionated accelerated chemoradiation for head and neck cancer during the recent first peak of the COVID-19 pandemic. Prospective data regarding this approach from randomised trials is lacking. In the PET NECK study, 564 patients with squamous cell carcinoma of the head and neck receiving definitive chemoradiation were randomised to either planned neck dissection or PET CT scan guided surveillance. In this surgical trial, three radiotherapy fractionation schedules delivered over 7, 6 or 4 weeks were permitted with synchronous chemotherapy. The purpose of this study was to determine efficacy and quality of life outcomes associated with the use of these schedules. Primary local control and overall survival in addition to quality of life measures at immediately post treatment and 6, 12 and 24 months post-treatment were compared between the three fractionation cohorts. In the 525 patients where fractionation data was available, 181 (34%), 288 (55%) and 56 (11%) patients received 68–70 Gy in 34–35 fractions (#), 60–66 Gy in 30# and 55 Gy in 20# respectively. At a minimum follow up of two years following treatment there was no significant difference between the three fractionation schemes in local control, overall survival or any quality of life measure. Despite the obvious limitations of this study, some data is provided to support the use of hypofractionated accelerated chemoradiation to avoid delays in cancer treatment and reduce hospital visits during the peak of a pandemic. Data from on-going randomised trials examining hypofractionated chemoradiation may be useful for selecting fractionation schedules during future pandemics.

AB - There has been increased interest in hypofractionated accelerated chemoradiation for head and neck cancer during the recent first peak of the COVID-19 pandemic. Prospective data regarding this approach from randomised trials is lacking. In the PET NECK study, 564 patients with squamous cell carcinoma of the head and neck receiving definitive chemoradiation were randomised to either planned neck dissection or PET CT scan guided surveillance. In this surgical trial, three radiotherapy fractionation schedules delivered over 7, 6 or 4 weeks were permitted with synchronous chemotherapy. The purpose of this study was to determine efficacy and quality of life outcomes associated with the use of these schedules. Primary local control and overall survival in addition to quality of life measures at immediately post treatment and 6, 12 and 24 months post-treatment were compared between the three fractionation cohorts. In the 525 patients where fractionation data was available, 181 (34%), 288 (55%) and 56 (11%) patients received 68–70 Gy in 34–35 fractions (#), 60–66 Gy in 30# and 55 Gy in 20# respectively. At a minimum follow up of two years following treatment there was no significant difference between the three fractionation schemes in local control, overall survival or any quality of life measure. Despite the obvious limitations of this study, some data is provided to support the use of hypofractionated accelerated chemoradiation to avoid delays in cancer treatment and reduce hospital visits during the peak of a pandemic. Data from on-going randomised trials examining hypofractionated chemoradiation may be useful for selecting fractionation schedules during future pandemics.

KW - COVID 19

KW - Fractionation

KW - Head and neck cancer

KW - Hypofractionated chemoradiation

KW - Pandemic

UR - http://www.scopus.com/inward/record.url?scp=85097759635&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2020.105112

DO - 10.1016/j.oraloncology.2020.105112

M3 - Article

AN - SCOPUS:85097759635

VL - 113

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

M1 - 105112

ER -